. 2018 Oct 30;27(7):2453–2462. doi: 10.1007/s00520-018-4523-4

Table 3.

Analysis of putative predictors of actionable distress

	Number of actionable DT	Number of visits^a	Percent of visits with actionable DT	Odds ratio (95% CI)	P value^c
Survivorship status					0.065
Surviving ≥ 5 years	95	331	28.7	Ref
Surviving < 5 years	55	269	20.4	0.64 (0.38, 1.07)
On treatment	300	924	32.5	1.19 (0.76, 1.88)
Age^b					0.738
< 25	80	311	25.7	Ref
25–35	124	419	29.6	1.20 (0.64, 2.25)
36–50	98	356	27.5	1.08 (0.60, 1.94)
> 50	147	437	33.6	1.45 (0.75, 2.77)
Sex					0.957
Female	255	867	29.4	Ref
Male	195	657	29.7	1.01 (0.64, 1.61)
HL subtype^b					0.895
Classical	397	1341	29.6	Ref
Other	51	167	30.5	0.96 (0.50, 1.83)
Risk strata^b					0.954
Early, favorable	80	269	29.7	Ref
Early, unfavorable	145	514	28.2	0.93 (0.54, 1.59)
Advanced	215	723	29.7	1.00 (0.60, 1.67)
Stage^b					0.837
Stage I	33	113	29.2	Ref
Stage II	192	670	28.7	0.97 (0.49, 1.95)
Stage III	99	378	26.2	0.86 (0.39, 1.90)
Stage IV	116	345	33.6	1.23 (0.55, 2.76)
Treatment^d					0.394
Chemotherapy only	178	595	29.9	Ref
Chemotherapy/radiation	120	316	38.0	1.43 (0.71, 2.92)
Radiation only	2	13	15.4	0.43 (0.13, 1.39)
Charlson Score					0.14
No comorbidities present	320	1172	27.3	Ref
Comorbidities present	130	352	36.9	1.56 (0.92, 2.65)

Results are derived from univariable generalized estimating equations

DT distress thermometer, CI confidence interval

^aVisits where a distress thermometer was completed

^bPatients with unknown status are excluded from analyses presented in this table

^cScore test

^dIn patients on treatment only